Trellus Health (FRA:85Q) EV-to-EBIT: 0.12 (As of Sep. 02, 2026) — 69% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Trellus Health EV-to-EBIT?

Trellus Health FRA:85Q EV-to-EBIT is 0.12 as of Sep. 02, 2026, which is 69% below its 10-year median of 0.39. The stock has 2 warning signs investors should review. Among 477 Healthcare Providers & Services companies, Trellus Health ranks better than 98.95% on this metric.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Trellus Health's Enterprise Value is €-0.75 Mil. Trellus Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was €-6.41 Mil. Therefore, Trellus Health's EV-to-EBIT for today is 0.12.

The historical rank and industry rank for Trellus Health's EV-to-EBIT or its related term are showing as below:

FRA:85Q' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.12   Med: 0.39   Max: 0.51
Current: 0.12

During the past 5 years, the highest EV-to-EBIT of Trellus Health was 0.51. The lowest was -0.12. And the median was 0.39.

FRA:85Q's EV-to-EBIT is ranked better than
98.95% of 477 companies
in the Healthcare Providers & Services industry
Industry Median: 15.49 vs FRA:85Q: 0.12

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Trellus Health's Enterprise Value for the quarter that ended in Jun. 2025 was €-0.47 Mil. Trellus Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was €-6.41 Mil. Trellus Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was 1,361.36%.


Trellus Health  (FRA:85Q) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Trellus Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2025 ) =EBIT / Enterprise Value (Q: Jun. 2025 )
=-6.408/-0.470706
=1,361.36 %

Trellus Health's Enterprise Value for the quarter that ended in Jun. 2025 was €-0.47 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Trellus Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was €-6.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trellus Health EV-to-EBIT Related Terms


Trellus Health EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Trellus Health's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trellus Health EV-to-EBIT Chart

Trellus Health Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
0.00 -11.87 -0.07 0.81 0.41

Trellus Health Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.81 0.00 0.41 0.00

FRA:85Q vs VEEV, BTSG, TEM: EV-to-EBIT Comparison

For the Health Information Services subindustry, Trellus Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trellus Health EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Trellus Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Trellus Health's EV-to-EBIT falls into.



Trellus Health EV-to-EBIT Calculation

Trellus Health's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-0.748/-6.408
=0.12

Trellus Health's current Enterprise Value is €-0.75 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Trellus Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was €-6.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of 0.12 mean?
Trellus Health (FRA:85Q) has a EV-to-EBIT of 0.12 as of Sep. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Trellus Health and its competitors. This is 69% below median its historical median of 0.39. According to the industry distribution chart, Trellus Health ranks #5 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 1%.
Is Trellus Health's EV-to-EBIT too high?
Trellus Health's current EV-to-EBIT of 0.12 is 69% below median its 10-year median of 0.39. The Healthcare Providers & Services industry median EV-to-EBIT is 15.49. Trellus Health's value of 0.12 is 99.2% below this industry median. Based on the distribution chart, Trellus Health ranks #5 out of 477 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Trellus Health's EV-to-EBIT compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Trellus Health ranks #5 out of 477 companies for EV-to-EBIT. This places Trellus Health in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.49. Trellus Health's value of 0.12 is 99.2% below this benchmark. While the company's 10-year median is 0.39 vs. the industry median of 15.49, Trellus Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.49, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trellus Health's current EV-to-EBIT of 0.12 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Trellus Health and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trellus Health's current EV-to-EBIT is 0.12, which is 69% below median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trellus Health stock overvalued right now?
Trellus Health (FRA:85Q) has a current EV-to-EBIT of 0.12. The current EV-to-EBIT is 0.12, which is 69% below median its 10-year median of 0.39 and 99.2% below the Healthcare Providers & Services industry median of 15.49. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Trellus Health (FRA:85Q), the current EV-to-EBIT is 0.12 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Trellus Health Business Description

Other Exchanges TRLS:UK
Address 19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Trellus Health PLC is commercializing the provision of digital chronic condition management solutions for employers and health plans that utilize the scientifically validated GRITT resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate to coordinate and deliver personalized care. The company is initially focused on Inflammatory Bowel Diseases, which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis but considers its approach to have potential utility and demand across many chronic conditions.